The treatment of CLL has undergone a transition from chemotherapy to small-molecule targeted therapy and cellular immunotherapy, including novel CD20 monoclonal antibodies, Bruton’s tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinase inhibitors and CAR-T-cell treatment [49]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.